ByTrending Posts
Atrium Therapeutics Spins Out with $270M Cash from…
Published by BioNextAI Media – Atrium Therapeutics (Nasdaq: ATRM) launched as an independent public company following Novartis’ $12 billion…
Azitra Spotlights ATR-12 Phase 1b Data at BIO…
Published by BioNextAI Media – Azitra, Inc. (NYSE American: AZTR) takes center stage at the BIO Investment & Growth…
BioMarin’s Roctavian Withdrawal—$240M Q4 Charge, <200 U.S. Patients…
Published by BioNextAI Media – BioMarin Pharmaceutical Inc. voluntarily withdrew its pioneering hemophilia A gene therapy ROCTAVIAN (valoctocogene roxaparvovec-rvox)…
Boehringer’s Hernexeos Secures Record 44-Day FDA Nod via…
Published by BioNextAI Media – Boehringer Ingelheim’s HERNEXEOS (zongertinib tablets) snagged ultra-fast FDA accelerated approval in just 44 days…
AbbVie’s $380M North Chicago API Expansion—300 Jobs, AI…
Published by BioNextAI Media – AbbVie is injecting $380 million into two new active pharmaceutical ingredient (API) facilities at…
Pfizer’s 1,200-GPU AI Blitz—$500M Bet to Slash 18-24…
Published by BioNextAI Media – Pfizer is deploying over 1,200 NVIDIA H100/H200 GPUs in a $500-600 million infrastructure overhaul,…
BioNextAI Media Report: Merck-Mayo Clinic AI Pact—5 Petabytes…
Published by BioNextAI Media – Merck has forged a high-octane research collaboration with Mayo Clinic, fusing 5 petabytes of…
BioNextAI Media Report: Keytruda’s Ovarian Cancer Combo Triumph—28%…
Published by BioNextAI Media – Merck’s KEYTRUDA (pembrolizumab) delivered compelling Phase 3 data from combination regimens in ovarian cancer,…
BioNextAI Media Report: Merck’s Gardasil Cuts—$200M Savings, 150…
Published by BioNextAI Media – In a calculated response to softening markets, Merck is halting production of its HPV…
Trending Posts
Latest Stories
Strategic Industry Analysis: What the Biggest Biopharma Deals of 2025 Reveal About the Future of Drug Innovation
The global biopharmaceutical industry experienced a powerful wave of strategic dealmaking in 2025 as major…
EU Regulators Back CAMCEVI: A Key Step Toward Expanding Prostate Cancer Treatment Options
Foresee Pharmaceuticals has received a positive opinion from the Committee for Medicinal Products for Human…
Can aTyr Pharma’s Upcoming FDA Meeting Accelerate the Path to Approval for Efzofitimod?
aTyr Pharma has reported its fourth-quarter and full-year 2025 financial results while outlining a pivotal…
Did the Zealand Pharma–Roche Obesity Partnership Hit an Early Roadblock?
A closely watched obesity drug collaboration between Zealand Pharma and Roche has encountered an unexpected…
Gallery
